Matthew Gline
CEO at Roivant Sciences Ltd.
Sits on 2 boards. Last updated September 28, 2026
Time on boards
- Boards served
- 2
- Current seats
- 2
- Board service
- 6 years
- Director since
- 2023
6 years of board service in total across 2 boards, counting each seat separately. Longest: Roivant Sciences Ltd., 3 years.
Chief executive roles
Shareholder support
Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
Arbutus Biopharma Corporation May 26, 202686.5%
-
Roivant Sciences Ltd. September 10, 202573.6%
-
Arbutus Biopharma Corporation May 21, 202594.3%
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
| Date | Company | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Oct 16, 2026 | Roivant Sciences Ltd. | Shares withheld for tax | −34,638 | $33.53 | $1,161,412 |
| Sep 30, 2026 | Roivant Sciences Ltd. | Shares withheld for tax | −76,171 | $36.57 | $2,785,573 |
| Jun 30, 2026 | Roivant Sciences Ltd. | Shares withheld for tax | −76,171 | $35.39 | $2,695,692 |
| Apr 16, 2026 | Roivant Sciences Ltd. | Open-market sale | −289,774 | $29.16 | $8,449,810 |
| Mar 31, 2026 | Roivant Sciences Ltd. | Shares withheld for tax | −304,684 | $27.70 | $8,439,747 |
| Mar 30, 2026 | Roivant Sciences Ltd. | Option exercise | +97,319 | — | — |
| Mar 30, 2026 | Roivant Sciences Ltd. | Shares withheld for tax | −53,826 | $26.41 | $1,421,545 |
| Dec 15, 2025 | Roivant Sciences Ltd. | Option exercise | +234,096 | $4.06 | $950,430 |
| Dec 15, 2025 | Roivant Sciences Ltd. | Open-market sale | −230,357 | $21.68 | $4,994,140 |
| Dec 15, 2025 | Roivant Sciences Ltd. | Other | −3,739 | $21.68 | $81,062 |
| Dec 15, 2025 | Roivant Sciences Ltd. | Option exercise | +1,363,711 | $12.68 | $17,291,855 |
| Dec 15, 2025 | Roivant Sciences Ltd. | Open-market sale | −566,116 | $21.68 | $12,273,395 |
| Dec 15, 2025 | Roivant Sciences Ltd. | Other | −797,595 | $21.68 | $17,291,860 |
| Dec 15, 2025 | Roivant Sciences Ltd. | Option exercise | +2,272,852 | $12.68 | $28,819,763 |
| Dec 15, 2025 | Roivant Sciences Ltd. | Open-market sale | −943,527 | $21.68 | $20,455,665 |
Questions about Matthew Gline
What boards is Matthew Gline on?
Matthew Gline sits on the boards of Arbutus Biopharma Corporation and Roivant Sciences Ltd.
What company is Matthew Gline the CEO of?
Matthew Gline is CEO of Roivant Sciences Ltd.
How long has Matthew Gline served on boards?
Our records show at least 6 years of board service across 2 boards, the earliest from 2023.
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.